The blood transfusion effect: clinical aspects

A M MacLeod

    Research output: Contribution to journalArticle

    7 Citations (Scopus)

    Abstract

    In 1973, Opelz et al. demonstrated a one-year renal transplant survival of 29% in patients who had never been transfused and 66% in those receiving over ten units of blood before transplantation. Subsequent reports were contradictory, but by the early 1980s it was generally accepted that pretransplant blood transfusions were beneficial. By 1983 only 4% of patients awaiting transplantation were untransfused. Since 1985 the data have again become much less clear. In 1987, Opelz showed no improvement in transplant survival, irrespective of whether immunosuppression was with cyclosporin or with conventional therapy. Recently, however, several American studies have again shown beneficial effects of transfusions particularly in patients less well matched for HLA antigens with their donor. There is evidence also that blood transfusion from the specific donor improves survival of a transplant from a living related donor. The risk of sensitisation can be minimised by giving cyclosporin along with the transfusion. Mechanism of the transfusion effect is unclear, but the following have been suggested: (a) clonal deletion or inactivation; (b) the induction of suppressor lymphocytes; (c) the presence of blocking alloantibodies or anti-idiotypic antibodies. There is clearly a need to determine from large studies whether the beneficial transfusion effect still exists, and also to determine whether, for example, numbers of rejection episodes which require expensive therapy are different in transfused and non-transfused patients.(ABSTRACT TRUNCATED AT 250 WORDS)
    Original languageEnglish
    Pages (from-to)123-6
    Number of pages4
    JournalImmunology Letters
    Volume29
    Issue number1-2
    Publication statusPublished - 1 Jul 1991

    Fingerprint

    Blood Transfusion
    Transplants
    Cyclosporine
    Transplantation
    Clonal Deletion
    Tissue Donors
    Isoantibodies
    Living Donors
    HLA Antigens
    Immunosuppression
    Anti-Idiotypic Antibodies
    Lymphocytes
    Kidney
    Therapeutics

    Keywords

    • Antibodies, Anti-Idiotypic
    • Blood Transfusion
    • Graft Survival
    • Humans
    • Kidney Transplantation
    • Lymphocytes
    • Receptors, Fc
    • T-Lymphocytes, Regulatory

    Cite this

    MacLeod, A. M. (1991). The blood transfusion effect: clinical aspects. Immunology Letters, 29(1-2), 123-6.

    The blood transfusion effect: clinical aspects. / MacLeod, A M.

    In: Immunology Letters, Vol. 29, No. 1-2, 01.07.1991, p. 123-6.

    Research output: Contribution to journalArticle

    MacLeod, AM 1991, 'The blood transfusion effect: clinical aspects', Immunology Letters, vol. 29, no. 1-2, pp. 123-6.
    MacLeod, A M. / The blood transfusion effect: clinical aspects. In: Immunology Letters. 1991 ; Vol. 29, No. 1-2. pp. 123-6.
    @article{2d986164eb2d49bc851b1cb139fa2cb7,
    title = "The blood transfusion effect: clinical aspects",
    abstract = "In 1973, Opelz et al. demonstrated a one-year renal transplant survival of 29{\%} in patients who had never been transfused and 66{\%} in those receiving over ten units of blood before transplantation. Subsequent reports were contradictory, but by the early 1980s it was generally accepted that pretransplant blood transfusions were beneficial. By 1983 only 4{\%} of patients awaiting transplantation were untransfused. Since 1985 the data have again become much less clear. In 1987, Opelz showed no improvement in transplant survival, irrespective of whether immunosuppression was with cyclosporin or with conventional therapy. Recently, however, several American studies have again shown beneficial effects of transfusions particularly in patients less well matched for HLA antigens with their donor. There is evidence also that blood transfusion from the specific donor improves survival of a transplant from a living related donor. The risk of sensitisation can be minimised by giving cyclosporin along with the transfusion. Mechanism of the transfusion effect is unclear, but the following have been suggested: (a) clonal deletion or inactivation; (b) the induction of suppressor lymphocytes; (c) the presence of blocking alloantibodies or anti-idiotypic antibodies. There is clearly a need to determine from large studies whether the beneficial transfusion effect still exists, and also to determine whether, for example, numbers of rejection episodes which require expensive therapy are different in transfused and non-transfused patients.(ABSTRACT TRUNCATED AT 250 WORDS)",
    keywords = "Antibodies, Anti-Idiotypic, Blood Transfusion, Graft Survival, Humans, Kidney Transplantation, Lymphocytes, Receptors, Fc, T-Lymphocytes, Regulatory",
    author = "MacLeod, {A M}",
    year = "1991",
    month = "7",
    day = "1",
    language = "English",
    volume = "29",
    pages = "123--6",
    journal = "Immunology Letters",
    issn = "0165-2478",
    publisher = "Elsevier",
    number = "1-2",

    }

    TY - JOUR

    T1 - The blood transfusion effect: clinical aspects

    AU - MacLeod, A M

    PY - 1991/7/1

    Y1 - 1991/7/1

    N2 - In 1973, Opelz et al. demonstrated a one-year renal transplant survival of 29% in patients who had never been transfused and 66% in those receiving over ten units of blood before transplantation. Subsequent reports were contradictory, but by the early 1980s it was generally accepted that pretransplant blood transfusions were beneficial. By 1983 only 4% of patients awaiting transplantation were untransfused. Since 1985 the data have again become much less clear. In 1987, Opelz showed no improvement in transplant survival, irrespective of whether immunosuppression was with cyclosporin or with conventional therapy. Recently, however, several American studies have again shown beneficial effects of transfusions particularly in patients less well matched for HLA antigens with their donor. There is evidence also that blood transfusion from the specific donor improves survival of a transplant from a living related donor. The risk of sensitisation can be minimised by giving cyclosporin along with the transfusion. Mechanism of the transfusion effect is unclear, but the following have been suggested: (a) clonal deletion or inactivation; (b) the induction of suppressor lymphocytes; (c) the presence of blocking alloantibodies or anti-idiotypic antibodies. There is clearly a need to determine from large studies whether the beneficial transfusion effect still exists, and also to determine whether, for example, numbers of rejection episodes which require expensive therapy are different in transfused and non-transfused patients.(ABSTRACT TRUNCATED AT 250 WORDS)

    AB - In 1973, Opelz et al. demonstrated a one-year renal transplant survival of 29% in patients who had never been transfused and 66% in those receiving over ten units of blood before transplantation. Subsequent reports were contradictory, but by the early 1980s it was generally accepted that pretransplant blood transfusions were beneficial. By 1983 only 4% of patients awaiting transplantation were untransfused. Since 1985 the data have again become much less clear. In 1987, Opelz showed no improvement in transplant survival, irrespective of whether immunosuppression was with cyclosporin or with conventional therapy. Recently, however, several American studies have again shown beneficial effects of transfusions particularly in patients less well matched for HLA antigens with their donor. There is evidence also that blood transfusion from the specific donor improves survival of a transplant from a living related donor. The risk of sensitisation can be minimised by giving cyclosporin along with the transfusion. Mechanism of the transfusion effect is unclear, but the following have been suggested: (a) clonal deletion or inactivation; (b) the induction of suppressor lymphocytes; (c) the presence of blocking alloantibodies or anti-idiotypic antibodies. There is clearly a need to determine from large studies whether the beneficial transfusion effect still exists, and also to determine whether, for example, numbers of rejection episodes which require expensive therapy are different in transfused and non-transfused patients.(ABSTRACT TRUNCATED AT 250 WORDS)

    KW - Antibodies, Anti-Idiotypic

    KW - Blood Transfusion

    KW - Graft Survival

    KW - Humans

    KW - Kidney Transplantation

    KW - Lymphocytes

    KW - Receptors, Fc

    KW - T-Lymphocytes, Regulatory

    M3 - Article

    VL - 29

    SP - 123

    EP - 126

    JO - Immunology Letters

    JF - Immunology Letters

    SN - 0165-2478

    IS - 1-2

    ER -